The GNPDA1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma line, designed for targeted disruption of the GNPDA1 gene. This loss-of-function model enables investigation of glucosamine-6-phosphate deaminase 1 function in a physiologically relevant epithelial context. The polyclonal format provides a heterogeneous pool of edited cells, ensuring robust representation of knockout phenotypes without selection for single-cell clonal derivatives.
A-549 cells, originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma, serve as a widely characterized model of human non-small cell lung cancer (NSCLC). These cells exhibit alveolar type II-like epithelial features and are extensively used in studies of cancer cell biology, drug response, and metabolic reprogramming. The A-549 background provides a defined genetic and epigenetic landscape in which to dissect the role of GNPDA1 in tumor metabolism.
GNPDA1 encodes a key enzyme that catalyzes the reversible deamination of glucosamine-6-phosphate to fructose-6-phosphate and ammonia, directly linking the hexosamine biosynthesis pathway to glycolysis. This reaction modulates intracellular pools of UDP-GlcNAc, the essential donor substrate for O-GlcNAcylation and N-glycan biosynthesis. GNPDA1 functions downstream of the transcription factor MYC and is regulated by glucose availability and nutritional stress. Its product fructose-6-phosphate feeds into glycolysis, while ammonia contributes to nucleotide synthesis. GNPDA1 interacts with hexosamine pathway enzymes including GNPNAT1 and O-GlcNAc transferase, and its activity influences global protein post-translational modifications and nutrient-sensing signaling networks.
In the A-549 lung adenocarcinoma model, GNPDA1 ablation allows dissection of how hexosamine pathway flux contributes to the malignant phenotype. Altered UDP-GlcNAc levels downstream of GNPDA1 can disrupt O-GlcNAcylation of oncogenic and tumor-suppressor proteins, potentially affecting proliferation, migration, invasion, and resistance to chemotherapy. This knockout model is thus pivotal for elucidating metabolic vulnerabilities specific to NSCLC, where the hexosamine pathway is often co-opted to support rapid growth and survival under stress.
Researchers can employ this polyclonal knockout cell product to study hexosamine pathway flux using metabolomic profiling, assess O-GlcNAc modifications via western blotting and immunofluorescence, and measure glycosylation changes by lectin blotting. Functional assays for proliferation, migration/invasion, and drug sensitivity can be combined with RT-qPCR analysis of downstream targets. The model supports investigations into the interplay between nutrient availability, MYC-driven transcription, and post-translational modifications in lung adenocarcinoma. For additional details, please contact Ascent Research.
